Liver Transplant; Complications
137
27
31
47
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
2.9%
4 terminated out of 137 trials
92.2%
+5.7% vs benchmark
10%
14 trials in Phase 3/4
11%
5 of 47 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 47 completed trials
Clinical Trials (137)
Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).
Perioperative Hemostasis Management in Liver Transplantation
Angiotensin II in Liver Transplantation
Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation
Effect of Cognitive Therapy on Immunosuppressive Treatment Compliance and Motivation
Intraoperative Assessment of Renal Tissue Oxygenation Using NIRS
Single-Cell and Spatial Transcriptomics Analysis of Steatotic Donor Liver Susceptibility to Post-Transplant Injury
Starzl Network Patient Reported Outcomes
Verification of Risk Factors of Thrombohemorrhagic Complications in Recipients After Related Liver Transplantation
Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)
Effects of Comedy Therapy on Pain and Comfort Levels in Liver Transplant Recipients
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation
Effects of Comedy Therapy on Anxiety and Vital Signs in Transplant Recipients
Prehabilitation and Posttransplant Training Program in Liver Transplantation
Angiotensin 2 for AKI After OLT
CytOSorb TreatMent Of Critically Ill PatientS Registry
Extended-Release Tacrolimus Following Liver Transplantation
The Efficacy of Intravenous Amino Acids in Reducing the Occurrence of AKI After Live Donor Liver Transplant